By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Indian contract research organization GVK Biosciences said on Monday that it has entered into a drug screening deal with the Moulder Center for Drug Discovery Research at Temple University.

The multi-year agreement calls for GVK Bio to validate targets and identify and optimize small molecules in specific therapeutic areas, such as cardiovascular, metabolic, and central nervous system disorders.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Cell this week: map of human protein interactions, mutant phenotype variability in organisms of the same species from different genetic backgrounds, and more.

Critics call the Fred Hutchinson Cancer Research Center's Gary Gilliland's prediction of cancer cures within 10 years "out of touch with reality" and "irresponsible."

Ivan Oransky discusses the need for reproducibility research at The Conversation.

The San Diego Union-Tribune posts videos from Biocom's Speaker Series with Illumina's Jay Flatley, who discusses Roche's failed hostile takeover bid.